Spondyloarthritis & psoriatic arthritis
Gender-specific differences in patients with psoriatic arthritis receiving ustekinumab or tumour necrosis factor inhibitor: real-world data
Authors' conclusion
Before starting bDMARDs, females had more severe disease than males and a lower percentage reached favourable disease states, with lower persistence of treatment after 12 months.
Study context
- Population
- Patients with PsA starting a bDMARD (ustekinumab or TNF inhibitor (TNFi)), Europe
- Participants
- 512 vs 417
- Comparison
- Female vs male patients with PsA starting ustekinumab or TNFi
- Femalesn = 512
- Malesn = 417reference
Methodological detailsEuropean
- European
Primary result
As reported in the abstract
Outcomes at 12 months by gender
- Improvements in scores were smaller in female than male patients
Further findings
| Outcome | P value |
|---|---|
| Treatment persistenceLower in females than males | P ≤ 0.001 |
Improvement in scores
- Improvements in scores were smaller in female than male patients
Treatment persistence
- Lack of effectiveness was the predominant reason to stop, irrespective of gender and bDMARD
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Gender-specific differences in patients with psoriatic arthritis receiving ustekinumab or tumour necrosis factor inhibitor: real-world data. Rheumatology (Oxford). Published 22 February 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →